Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 24, 2016. The report announces positive headline results from the Salford Lung Study (SLS), a Phase IIIb multi-centre, open-label randomised controlled trial conducted in collaboration with Innoviva, Inc. The study evaluated the effectiveness of Relvar Ellipta (fluticasone furoate/vilanterol or FF/VI) in treating Chronic Obstructive Pulmonary Disease (COPD) within an everyday clinical practice setting.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a regulatory announcement focused exclusively on clinical trial results and product safety information.
Material Changes and Clinical Results
The primary material update concerns the clinical performance of Relvar Ellipta compared to "usual care" (standard treatments including LAMA, LABA, and ICS monotherapies or combinations):
- Exacerbation Reduction: In the primary effectiveness analysis, patients treated with FF/VI 100/25mcg achieved a statistically significant 8.41% reduction in the rate of moderate or severe exacerbations compared to usual care (p=0.025).
- Safety Profile: The incidence of serious adverse events (SAE) was similar between the FF/VI group (29%) and the usual care group (27%).
- Pneumonia Risk: FF/VI demonstrated non-inferiority versus usual care regarding pneumonia, an SAE of special interest (7% FF/VI vs. 6% usual care).
- Study Population: The trial involved 2,802 patients randomised 1:1, with a mean age of 67 years. The primary analysis focused on 2,269 patients who had exacerbated in the previous 12 months.
Guidance, Outlook, and Risks
Outlook and Commentary: Management described the study as "ground-breaking" and noted that the results could transform the understanding of COPD treatment in everyday practice. Analyses remain ongoing, with further data expected in future publications. A second Salford Lung Study in asthma patients is underway, with results expected in 2017.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks described in GSK's 2015 Form 20-F. Specific safety risks for Relvar/Breo Ellipta include:
- Increased risk of asthma-related death associated with long-acting beta 2-agonists (LABA).
- Increased incidence of pneumonia, including hospitalisations and fatal events.
- Contraindications for acute bronchospasm relief and severe hypersensitivity.
- Potential for cardiovascular effects, bone mineral density decreases, and ocular issues (glaucoma, cataracts).
Investor Verification Checklist
- Verify the full statistical analysis of the Salford Lung Study in upcoming peer-reviewed publications.
- Monitor the timeline and results of the second Salford Lung Study focused on asthma patients (expected 2017).
- Review GSK's 2015 Annual Report on Form 20-F for detailed risk factors and financial context not included in this announcement.
- Assess the commercial impact of the "superiority" finding on Relvar/Breo Ellipta market share versus competitor COPD therapies.
- Confirm regulatory responses to the pneumonia non-inferiority data from the European Medicines Agency (EMA).